17054-27-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(Benzyloxy)-4-bromobenzoic acid 98 is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drug molecules. Its unique structure allows for the creation of compounds with specific therapeutic properties, enhancing the range of treatments available for various medical conditions.
Used in Chemical Industry:
In the chemical industry, 3-(Benzyloxy)-4-bromobenzoic acid 98 is employed as a versatile intermediate for the production of specialty chemicals. Its chemical properties make it suitable for use in a wide array of applications, from the creation of dyes and pigments to the development of advanced materials with specific chemical or physical properties.
Used in Agrochemical Production:
3-(Benzyloxy)-4-bromobenzoic acid 98 is also utilized in the agrochemical sector as an intermediate for the synthesis of various agrochemicals. Its role in this industry is crucial for the development of new pesticides, herbicides, and other agricultural chemicals that are essential for maintaining crop health and productivity.
It is imperative to handle 3-(Benzyloxy)-4-bromobenzoic acid 98 with care and adhere to safety protocols when working with it in laboratory or industrial environments to ensure the safety of personnel and the integrity of the compound.

InChI:InChI=1/C14H11BrO3/c15-12-7-6-11(14(16)17)8-13(12)18-9-10-4-2-1-3-5-10/h1-8H,9H2,(H,16,17)

Upstream product

• 124318-23-6 3-Benzyloxy-4-brombenzoesaeure-benzylester 
• 14348-38-0 4-bromo-3-hydroxybenzoic acid 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 440105-06-6 1,1-dimethylethyl 3-benzyloxy-4-[6-benzyloxy-2-(1,3-dioxan-2-yl)benzoyl]benzoate 
• 440105-07-7 3-benzyloxy-4-[6-benzyloxy-2-(1,3-dioxan-2-yl)benzoyl]benzoic acid 
• 440105-05-5 4-tert-butyloxycarbonyl-2-benzyloxybenzoic acid 
• 693232-04-1 4-bromo-3-benzyoxybenzamide 
• 693232-05-2 3-benzyloxy-4-bromobenzonitrile 
• 247186-50-1 4-bromo-3-benzyloxybenzoic acid 1,1-dimethylethyl ester 
• 17054-28-3 3-Benzyloxy-4-brombenzoylchlorid 

Relevant academic research and scientific papers

2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

A 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented by the generalformula (1): [Chemical formula 1] (1) or a pharmaceutically acceptable saltthereof. They are useful as a therapeutic/preventive agent for diabetes, diabeticnephropathy, or glomerulosclerosis.

Synthesis of Benzyloxybromobenzonitriles

The synthesis of four new benzyloxybromobenzonitriles including: 2-benzyloxy-4-bromobenzonitrile (3), 3-benzyloxy-4-bromobenzonitrile (7), 5-benzyloxy-2-bromobenzonitrile (11) and 3-benzyloxy-2-bromobenzonitrile (12) is reported.

Synthesis and protein kinase inhibitory activity of balanol analogues with modified benzophenone subunits

A series of analogues of the protein kinase C (PKC) inhibitory natural product balanol which bear modified benzophenone subunits are described. The analogues were designed with the goal of uncovering structure -activity features that could be used in the development of PKC inhibitors with a reduced polar character compared to balanol itself. The results of these studies suggest that most of the benzophenone features found in the natural product are important for obtaining potent PKC inhibitory compounds. However, several modifications were found to lead to selective inhibitors of the related enzyme protein kinase A (PKA), and several specific modifications to the polar structural elements of the benzophenone were found to provide potent PKC inhibitors. In particular, it was found that replacement of the benzophenone carboxylate with bioisosteric equivalents could lead to potent analogues. Further, a tolerance for lipophilic substituents on the terminal benzophenone ring was uncovered. These results are discussed in light of recently available structural information for PKA.